Innate Pharma S.A. Sponsored ADR Equity Repurchase (Common, Net)

Equity Repurchase (Common, Net) of IPHA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Equity Repurchase (Common, Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Equity Repurchase (Common, Net) for the quarter ending June 29, 2019 was $1.1 Thousand
  • Annual Equity Repurchase (Common, Net) for 2019 was $74 Million (a -0.05% decrease from previous year)
Visit stockrow.com/IPHA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Equity Repurchase (Common, Net) of Innate Pharma S.A. Sponsored ADR

Most recent Equity Repurchase (Common, Net)of IPHA including historical data for past 10 years.

Interactive Chart of Equity Repurchase (Common, Net) of Innate Pharma S.A. Sponsored ADR

Innate Pharma S.A. Sponsored ADR Equity Repurchase (Common, Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $0.0 $73.98
2018 $74.01

Business Profile of Innate Pharma S.A. Sponsored ADR

Sector: Medical
Industry: Drugs
Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.